Skip to main contentAI and Advanced
/
VENUSREM · BSEMarket ticker unavailable · configure an authorised index feed
VE
BSE · Equity shares · Biotechnology & Drugs-77.35 · -4.33%
Venus Remedies VENUSREM
NSE:INR 1,700
BSE:INR 1,710
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for VENUSREM
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,787.35
Day rangeINR 1,686.8 — INR 1,768.9
52-week rangeINR 423.7 — INR 2,043.15
Volume37,824
Market cap2,337.89
P/E10.66
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)769.6
Net Income (INR Cr)102.79
Rev Growth (5 Year %)7.02
EPS Growth (5 Year %)8.97
P/E Ratio10.66
Book Value426.16
EPS76.89
Price/BV4.01Computed
Research path: Interpret Venus Remedies's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
VENUSREMVenus Remedies1d · INR · BSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 853.7 | 715.72 | 626.82 |
| Cash Equivalents | 25.12 | 57.52 | 48.96 |
| Other Liabilities Total | 2.8 | 2.9 | 10.26 |
| Common Stock Total | 13.37 | 13.37 | 13.37 |
| Other Current Assets Total | 50.43 | 7.89 | 3.37 |
| Total Assets | 853.7 | 715.72 | 626.82 |
| Current Portof LT Debt/Capital Leases | 1.36 | Not available | Not available |
| Cash | 4.49 | 14.69 | 15.76 |
| Total Equity | 663.75 | 560.95 | 487.55 |
| Long Term Investments | 171.56 | 0.02 | 0.02 |
| Retained Earnings(Accumulated Deficit) | 650.38 | 455.49 | 381.89 |
| Total Common Shares Outstanding | 1.34 | 1.34 | 1.34 |
| Tangible Book Valueper Share Common Eq | 426.16 | 341.31 | 300.99 |
| Total Liabilities | 189.95 | 154.77 | 139.27 |
| Total Debt | 12.41 | 1.69 | 41.33 |
| Short Term Investments | 74.33 | 84.09 | 19.09 |
| Cashand Short Term Investments | 103.94 | 156.3 | 83.8 |
| Total Receivables Net | 111.46 | 183.12 | 147.92 |
| Deferred Income Tax | 14.34 | 15.58 | 10.92 |
| Accounts Receivable-Trade Net | 103.28 | 112.22 | 80.5 |
| Property/Plant/Equipment Total-Net | 188.98 | 151.09 | 154.41 |
| Total Current Liabilities | 161.76 | 136.29 | 79.42 |
| Total Inventory | 129.37 | 103.91 | 123.78 |
| Accounts Payable | 113.49 | 91.86 | 44.14 |
| Other Currentliabilities Total | 46.91 | 35.7 | 26 |
| Total Long Term Debt | 11.05 | 0 | 38.68 |
| Intangibles Net | 93.98 | 104.72 | 85.21 |
| Other Long Term Assets Total | 3.98 | 8.18 | 27.66 |
| Total Current Assets | 395.2 | 451.72 | 359.52 |
| Capital Lease Obligations | 11.05 | Not available | Not available |
| Accumulated Depreciation Total | Not available | -231.74 | -229.74 |
| Accrued Expenses | Not available | 7.04 | 6.63 |
| Long Term Debt | Not available | 0 | 38.68 |
| Other Equity Total | Not available | 3.76 | 3.96 |
| Prepaid Expenses | Not available | 0.5 | 0.63 |
| Additional Paid-In Capital | Not available | 88.33 | 88.33 |
| Property/Plant/Equipment Total-Gross | Not available | 351.65 | 362.72 |
| Notes Payable/Short Term Debt | Not available | 1.69 | 2.65 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.41
Price to Sale Ratio3.04
Growth
Debt 5Yr CAGR %-24.72
Margins
Operating Margin 12m15.22
Operating Margin 5y Avg8.33
Net Profit Margin 12m13.45
Net Profit Margin 5y7.69
Yield
Dividend Yield %0.56
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk56.6
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,937.7 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,369.6 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,970.35 | 1.68 L | 72.73 | — |
| Cipla | INR 1,408.7 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,122 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 41.76%
- FII
- 2.92%
- Other
- 55.32%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 9 December 2025Market news · 9 Dec 2025, 6:56 am
Sumeet Bagadia recommends five breakout stocks to buy today - Latent View Analytics, Cantabil Retail India Limited, Gujarat Ambuja Exports, Venus Remedies, and Jindal Stainless.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 15 July 2025Market news · 15 Jul 2025, 6:52 am
Sumeet Bagadia recommends five breakout stocks to buy today: CEAT, V I P Industries, Blue Jet Healthcare, HEG, and Venus Remedies.
Venus Remedies stock jumps over 14% to 8-week high on FDA approval for anti-mircrobial resistance therapyMarket news · 17 Apr 2025, 2:10 pm
Shares of Venus Remedies rose 14.3% to ₹ 356.65 after the US FDA granted QIDP designation to its product VRP-034, targeting bloodstream infections. This designation offers regulatory benefits, highlighting the need for safer polymyxin therapies. The stock has rebounded 12% this month.
Smallcap pharma stock hits over 8% upper circuit after securing marketing nod for chemotherapy drugs; do you own?Market news · 21 Dec 2023, 5:38 pm
Venus Remedies gained over 8 per cent today after securing marketing authorisation for three variants of chemotherapy drugs in Israel and Colombia
Venus Remedies shares locked at 5% upper circuit as German arm gets Spanish regulator nod to market Meropenem in SpainMarket news · 22 Jun 2023, 11:47 am
Venus Remedies' German subsidiary Venus Pharma GmbH has received this approval for 500mg, 1g and 2g injections of this last-recourse antibiotic.
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.10.0000 per share(100%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results, Final Dividend & A.G.M.
- board MeetingsTo consider other business matters.
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Venus Remedies
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Venus Remedies Limited is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- VENUSREM
- BSE Code
- 526953
Questions
Stock FAQ
What is the symbol and ISIN of Venus Remedies?
Venus Remedies has the symbol VENUSREM and ISIN - INE411B01019.
What is the current price of Venus Remedies?
Venus Remedies is currently trading at INR 1,710.00.
What are the year high and year low of Venus Remedies?
Venus Remedies has a year high of INR 2,043.15 and a year low of INR 423.70.
What is the market capitalization of Venus Remedies?
Venus Remedies has a market capitalization of INR 2,337.89 crore.
What is the P/E ratio of Venus Remedies?
Venus Remedies has a P/E ratio of 10.66.
What is the dividend yield of Venus Remedies?
Venus Remedies has a dividend yield of 0.56%.
How is the financial performance of Venus Remedies based on revenue, net income, and EPS?
Venus Remedies has revenue of INR 769.60 crore, net income of INR 102.79 crore, and EPS of INR 76.92.
What is the book value of Venus Remedies?
Venus Remedies has a book value of INR 426.16.
What is the debt-to-equity ratio of Venus Remedies?
Venus Remedies has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Venus Remedies?
Venus Remedies has a price-to-book ratio of 4.01 and a price-to-sales ratio of 3.04.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.